[LCID Study Number: 2018-005WIRB]
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
To determine the incidence rate of all-cause mortality through Day 28 post-randomization associated with treatment withImipenem/ cilastatin/ relebacta (IMI/REL) compared to treatment with Piperacillin/tazobactam (PIP/TAZ) in subjects diagnosed with HABP/VABP in the modified intention-to treat (MITT) population.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-1641